LifeMD, Inc. — 2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021, compared with fiscal 2020. The filing presents annual results, not a standalone fourth-quarter income statement. LifeMD operates direct-to-patient telehealth brands and owns 85.6% of WorkSimpli, a PDF software subscription business.
Financial performance and position
| Metric | 2021 | 2020 | Change / context |
|---|---|---|---|
| Revenue | $92.9 million | $37.3 million | Up 149% |
| Telehealth revenue | $68.2 million | $30.6 million | Up 123%; 73% of 2021 revenue |
| WorkSimpli revenue | $24.7 million | $6.7 million | Up 267%; 27% of 2021 revenue |
| Gross profit / margin | $74.9 million / 80.6% | $28.4 million / 76.2% | Margin improved 4.4 percentage points |
| Operating expenses | $129.2 million | $86.3 million | Up 50%; selling and marketing was $82.5 million |
| Operating loss | $(54.3) million | $(57.8) million | Loss narrowed despite higher spending |
| Net loss | $(61.3) million | $(60.5) million | Loss widened slightly |
| Net loss attributable to common shareholders | $(61.8) million | $(63.4) million | Includes $0.9 million of Series A preferred dividends in 2021 |
| Cash from operating activities | $(33.1) million | $(12.1) million | Cash burn increased |
| Cash from investing activities | $(3.4) million | $(0.8) million | Primarily software development costs |
| Cash from financing activities | $68.6 million | $21.0 million | Primarily equity and preferred-stock offerings |
| Cash at year-end | $41.3 million | $9.2 million | Up $32.1 million |
| Working capital | $22.1 million | $(1.5) million | Improved substantially |
At December 31, 2021, total assets were $49.9 million, total liabilities were $24.1 million, and stockholders’ equity was $21.7 million. Current liabilities included $20.7 million of accounts payable and accrued expenses, including $2.0 million of sales tax payable. Notes payable, net, were $63,400; the $15.0 million June 2021 secured debenture was repaid in October. The company also had $4.1 million of Series B preferred stock reported as mezzanine equity and 1.4 million shares of Series A preferred stock carrying an 8.875% cumulative annual dividend.
Recurring revenue was described as approximately 90% of total revenue. WorkSimpli reported 98% recurring revenue and more than 102,000 active subscriptions at year-end. Management reported more than 490,000 customers and patients served since inception.
Material changes and unusual items
- Telehealth and WorkSimpli both expanded rapidly. Gross margin improved, while selling and marketing costs rose 111% to $82.5 million to support customer acquisition.
- General and administrative expense fell to $39.6 million from $45.0 million, primarily because stock-based compensation declined to $12.1 million from $37.0 million. The 2020 amount included significant equity compensation.
- Other expenses rose to $7.0 million, including a $4.0 million loss on debt extinguishment and $3.0 million of net interest expense. The debt loss related mainly to repaying the June 2021 debenture.
- The October 2021 common and Series A preferred offerings generated approximately $55.3 million net before repayment of the debenture. The preferred shares are perpetual, senior to common stock for dividends and liquidation, and carry an 8.875% cumulative dividend.
- LifeMD increased its WorkSimpli ownership from 51% to approximately 85.6%. The LifeMD PC virtual primary-care platform launched in beta in Q4 2021 but recorded no 2021 revenue.
- Revenue recognition disclosure identifies a process limitation for certain orders whose title transfers upon customer delivery rather than shipment; management considered the resulting impact immaterial.
Outlook, risks and contingencies
Management expected revenue growth and operating efficiencies to improve liquidity, anticipated losses and cash burn continuing through the third quarter of 2022, and forecast cash-flow positivity by the fourth quarter of 2022. These are expectations, not guarantees. Management cited $59.5 million of remaining ATM capacity and $32 million available under the 2021 shelf, as well as its ability to curtail expenses. The filing also reports approximately $26.7 million of cash as of the filing date, versus $41.3 million at December 31, 2021; the provided text does not explain the intervening decrease.
- Profitability and financing: The company has a history of annual losses and negative operating cash flow; continued growth depends on improving cash generation or obtaining financing. Further equity issuance could dilute shareholders.
- Execution and competition: Results depend on customer acquisition and retention, marketing costs, provider and pharmacy relationships, successful expansion into new conditions, and competing against larger, better-resourced companies.
- Regulatory and data risks: Telehealth, prescribing, corporate-practice-of-medicine and fee-splitting rules vary by state and may change. Privacy, cybersecurity, product claims, and FDA/FTC compliance are also significant risks.
- Internal controls: Management concluded internal control over financial reporting was not effective at year-end due to material weaknesses in segregation of duties, accounting policies and procedures, and computer-system access/security and disaster recovery. Disclosure controls were also deemed ineffective. The auditor did not attest to internal-control effectiveness.
- Legal matters: Securities class-action suits and an accessibility lawsuit described in the filing were voluntarily dismissed. Three other actions were pending: Harborside Advisors alleged contract-related damages, with a potential loss not estimable; GoGoMeds sought $273,859 plus other relief and LifeMD counterclaimed; William Blair sought damages tied to an engagement letter, with potential loss not estimable. The company said it intended to defend these cases.
- Subsequent transactions: In January 2022, LifeMD acquired Cleared for $460,000 upfront plus $3.46 million in milestone payments and a performance-based earnout. In February 2022, WorkSimpli acquired resume-building software assets for $4.0 million, with additional seller payments tied to profits.
The auditor issued an unqualified opinion on the consolidated financial statements and identified stock-based compensation valuation and going-concern assessment as critical audit matters. Management concluded it had adequate liquidity for the 12 months following issuance, based partly on forecasts and access to financing.
Important facts for investors to verify
- Cash and cash burn after year-end: reconcile the reported $41.3 million year-end cash with $26.7 million reported as of the filing date, and assess the forecasted path to positive cash flow.
- Whether growth in telehealth and WorkSimpli subscriptions is producing improving customer economics, retention, and marketing efficiency—not just higher revenue.
- Progress in remediating the material weaknesses and whether controls are operating effectively in subsequent filings.
- Costs, integration, and performance milestones for the Cleared and ResumeBuild acquisitions, including any earnouts or assumed liabilities.
- Potential dilution from outstanding options, warrants, preferred securities, and future capital raises; the filing reports 3.9 million warrants and 4.3 million options outstanding at year-end.
- Developments and potential financial exposure in the pending Harborside, GoGoMeds, and William Blair litigation, and the status of the $2.0 million sales tax payable.